Clinical Trials Browser

OTHER_GOV × eribulin × Clear all

NCT05335473 2023-04-06

Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

Phase 1/2 Unknown

HR Positive HER2 Negative Advanced Breast Cancer

NCT02864030 2021-03-04

PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

Phase 4 Completed

Breast Neoplasms, Neurotoxicity Syndromes, Drug-Related Side Effects and Adverse Reactions